NeoGenomics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +14.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 10.2% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 12.6% | Better than 71% |
| Free cash flow CAGR (3Y) | -37.9% | Better than 8% |
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 43.2% | Better than 53% |
| Operating margin | -12.1% | Better than 14% |
| Net margin | -14.9% | Better than 14% |
| Return on equity | -12.4% | Better than 19% |
| Return on invested capital | -8.2% | Better than 19% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -12.7% | Better than 44% |
| 6-month return | 60.6% | Better than 97% |
| 12-month return (ex latest month) | 42.8% | Better than 80% |
| Distance below 52-week high | 26.5% | Better than 48% |
Financial Health C-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.3x | Better than 82% |
| Debt to assets | 30.1% | Better than 41% |
| Interest coverage | -28.4x | Better than 9% |
| Free cash flow / net income | 41.7% | Better than 11% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 77.8% | Better than 57% |
| Upside to average target | 66.7% | Better than 75% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 15.09
- Open
- 14.86
- Day range
- 14.63 - 15.14
- Avg price
- 14.83
- Volume
- 1.18M
- Turnover
- 17.46M
- Turnover ratei
- 1.00%
- Volume ratioi
- 0.81
- Amplitudei
- 3.38%
- 52-week rangei
- 7.07 - 20.15
Valuation
- P/Ei
- -17.64
- P/E (TTM)i
- -61.75
- P/Bi
- 2.39
- EPSi
- -0.84
- Book value / shi
- 6.19
- Net profit
- -108.69M
- Net assets
- 800.66M
Share structure
- Market cap
- 1.92B
- Float capi
- 1.75B
- Shares out
- 129.39M
- Float sharesi
- 118.11M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
26.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-257.28K net over the window
Short interest
- Shares short
- 13.13M
- % of floati
- 10.15%
- Days to coveri
- 6.67
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of NeoGenomics (NEO)?
NeoGenomics last traded at 14.82. This page shows a periodic quote snapshot. Check the displayed quote time.
What is NeoGenomics's market cap?
About 1.92B.
What is the P/E ratio of NeoGenomics?
The trailing twelve-month P/E is -61.75. The Valuation tab shows it against the stock's own five-year range.
Does NeoGenomics pay a dividend?
NeoGenomics does not currently pay a regular dividend.
Is NeoGenomics a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 24.71, which implies 66.7% upside from the current price. This is not investment advice.
What is NeoGenomics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates NeoGenomics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
NeoGenomics discussion 0 comments